Entyvio Continues to Show Benefits for Inflammatory Bowel Disease
Long-term results appear promising
The real-world clinical data showed that patients who received vedolizumab and had moderate to severe IBD experienced low rates of severe infections, and minimal malignancies and infusion-related reactions. Researchers reported that this is consistent with clinical trial data that revealed the safety profile and indicates that the long-term expected benefit of vedolizumab will likely be consistent with clinical trial results.
